Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Antibacterial composition

An antibacterial and composition technology, applied in the direction of antibacterial drugs, drug combination, drug delivery, etc., can solve the problems that it is difficult to treat Acinetobacter infection, and no effective drug has been found, so as to prevent Acinetobacter infection , the effect of reducing the burden

Pending Publication Date: 2022-01-04
NAT UNIV CORP TOKYO MEDICAL & DENTAL UNIV +1
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

On the other hand, for Acinetobacter, which is considered to be an important bacterium in severe pneumonia, there are drugs such as colistin and polymyxin B, which are considered to be effective to a certain extent, but they are used in Japan because of their It is not approved due to nephrotoxic side effects, etc., and it is difficult to treat Acinetobacter infection even with general antibacterial drugs (Non-Patent Document 1)
Furthermore, regarding drug-resistant Acinetobacter (multidrug-resistant Acinetobacter infection), no effective drug has been found, and the invention of new drugs is expected

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antibacterial composition
  • Antibacterial composition
  • Antibacterial composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0083] [Preparation of sample]

[0084] · Lysozyme-chitosan complex (LYZOX (registered trademark)) solution

[0085] As a solution of a complex (lysozyme-chitosan complex) obtained by binding lysozyme and chitosan, commercially available LYZOX (registered trademark, manufactured by Wako Filter Technology Co., Ltd.) was used. Commercially available LYZOX (registered trademark) is a powder containing chicken-derived lysozyme (about 14000 Da) and water-soluble chitosan (chitooligosaccharide) of about 5000 Da in a mass ratio of 1:1. Specifically, the above-mentioned lysozyme and water-soluble chitosan are mixed and dissolved in water, and after that, they are made into powder by freeze-drying, and further, under the conditions of sufficient temperature, humidity and days for the Maillard reaction to be completely completed, pass The Maillard reaction yielded the lysozyme-chitosan complex (LYZOX (registered trademark)) used in the present invention. The lysozyme-chitosan complex ...

experiment example 1

[0099] Experimental example 1 (bactericidal test)

[0100] In comparison with a mixture of lysozyme and chitosan and the like, the bactericidal activity of the lysozyme-chitosan complex (LYZOX (registered trademark)) against Acinetobacter and the like was measured.

[0101] Specifically, for the above-mentioned lysozyme-chitosan complex (LYZOX (registered trademark)) solution (2000 μg / mL, using physiological saline as a solvent), and a solution of a mixture of lysozyme and chitosan (lysozyme monomer solution [1000μg / mL] and chitosan monomer solution [1000μg / mL], use physiological saline as solvent), add 30μL of 1.0M phosphate buffer (pH7.2) in every 1.0mL solution, adjust Each solution was prepared to neutral pH (7.0-7.3). As a control, physiological saline (0.9% NaCl solution) was used. Acinetobacter bacterial suspensions or Pseudomonas aeruginosa bacterial suspensions were prepared as follows: Pseudomonas aeruginosa (NBRC 13275 or PAO1) or Acinetobacter baumannii (JCM 6841...

experiment example 2

[0104] Experimental example 2 (bactericidal test)

[0105] The bactericidal effect of Pseudomonas aeruginosa (NBRC 13275) on each concentration of the lysozyme-chitosan complex (LYZOX (registered trademark)) was measured. Specifically, as the above-mentioned lysozyme-chitosan complex (LYZOX (registered trademark)) solution, physiological saline (0.9% NaCl solution) was used as a solvent, and solutions having different concentrations (200 μg / mL, 2000 μg / mL, and 10000 μg / mL), the experiment was repeated in the same manner as in Experimental Example 1 above, and the bacterial count of Pseudomonas aeruginosa (NBRC 13275) was measured. The results are shown in Figure 2D . like Figure 2D As shown, the lysozyme-chitosan complex exhibited concentration-dependent bactericidal activity.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to View More

Abstract

Provided is an antibacterial composition against Acinetobacter. Provided are: a pharmaceutical composition which is for treating or preventing Acinetobacter infection, contains a complex in which lysozyme and chitosan are bound, and has an antibacterial property against Acinetobacter; and a pharmaceutical composition which is for treating or preventing Acinetobacter infection and contains a complex in which lysozyme and chitosan are bound.

Description

technical field [0001] The present invention relates to an antibacterial composition and the like having antibacterial properties against Acinetobacter. Background technique [0002] Nontuberculous acid-fast bacteria such as Pseudomonas aeruginosa or MRSA are infectious bacteria that cause respiratory tract infections. This infection is considered a problem due to its refractory nature. Recently, it has been clarified that a complex obtained by binding lysozyme to chitosan is effective against Pseudomonas aeruginosa and MRSA (Patent Document 1). On the other hand, for Acinetobacter, which is considered to be an important bacterium in severe pneumonia, there are drugs such as colistin and polymyxin B, which are considered to be effective to a certain extent, but they are used in Japan because of their It is not approved for reasons such as nephrotoxic side effects, and it is difficult to treat Acinetobacter infection even with general antimicrobials (Non-Patent Document 1)....

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61P11/00A61P31/04A61P43/00A61K9/06A61K9/08A61K9/12A61K9/70A61K47/36A61K47/55A61K47/61A61K38/46A61K31/722
CPCA61K9/70A61P43/00A61K47/61A61K31/722A61K38/46A61K9/12A61K47/36A61P11/00A61K9/06A61K9/08A61P31/04A61K38/47A61K47/64
Inventor 宫崎泰成影岛宏纪齐藤章
Owner NAT UNIV CORP TOKYO MEDICAL & DENTAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com